Material and Method: A total of 298 pleural fluid cases diagnosed from 2008 to 2009 in our laboratory were retrospectively identified as the study group. Evaluation results were classified in 5 groups as inconclusive, benign, atypical, suspicious and malignant, and compared with the biopsy results.
Results: Of the total 298 pleural fluid cases, 114 (38.3%) were females and 184 (61.7%) were males. The age range was between 15 and 89 with a mean value of 58.4±17.8. Of the cases, 3 (1%) were diagnosed as inadequate, 246 (82.6%) benign, 8 atypical, 10 suspicious, and 31 malignant by cytology. Among the cases who were diagnosed as malignant, 24 (8.1%) were reported as metastatic carcinoma and 7 (2.3%) as malignant mesothelioma. Of the 8 cases reported as atypical, biopsy results of 2 showed malignant mesothelioma, and of the 10 cases reported as suspicious, 1 case whose biopsy result was obtained was diagnosed as epidermoid carcinoma metastasis.
Conclusion: Cytological examination is the most valuable diagnostic method for pleural effusions which may have various etiological causes. The most common cause of pleural effusions in our region is metastatic carcinomas including those from the lung, breast and ovarian tumors, followed by malignant mesothelioma.
Pleural effusion is the excessive collection of fluid in the pleural space due to lung disease or systemic disorders. It can reflect systemic problems as disorders of any system or organ can affect the pleura[3-5]. Pleural effusion is frequent and easy to detect but it is not possible to always determine the etiology. The cytological investigation of pleural fluids is therefore a rapid, effective and noninvasive method to determine the etiology[6,7].
Although parapneumonic effusions take first place in the etiology of exudative pleural effusions, malignant effusions are seen to be the most common when fluids that require thoracentesis are taken into account. Lung and breast cancers are the most common cause of malignant pleural effusions. The first evaluation of patients with lung cancer reveals malignant pleural effusion at rate of approximately 15%[5].
The presence of malignant effusion is of great importance regarding the treatment and prognosis. For example, the presence of malignant effusion in lung cancer eliminates the possibility of surgical treatment while it is a sign of advanced disease and short survival in tumors of other organs[8].
Cytopathologic investigation is known to have a high diagnostic value in malignant pleural effusions[6,9-11]. We therefore investigated the distribution of cytopathologic diagnoses and the cyto-histopathologic correlation rates in this study.
Table I: Gender distribution of pleural cytology cases
Table II: Diagnostic subgroups for pleural fluid cytology
Table III: Tumor types comprising malignant pleural cytology
Table IV: Distribution of metastatic carcinomas by tumor type (pleural biopsy present/absent)
Figure 3: Microscopic appearance of malignant mesothelioma in the pleural fluid (Pap; x400).
The etiology of pleural effusion varies by region[15]. It has been reported that the etiology cannot be elucidated in up to 20% of the cases as pleural effusion can be caused by many diseases[16,17]. Non-malignant causes such as pneumonia, heart failure and liver disease are found in 80% of the cases while malignancy-related reasons make up the remaining 20%[12]. Gönlügür et al.[15] have found malignant mesothelioma to take first place among the causes of pleural effusion, followed by parapneumonic effusions, tuberculous pleurisy and congestive heart failure. Malignant diseases are one of the most common causes other than tuberculosis of exudative pleural effusions[4,18]. A malignant pleural effusion is recognized by demonstrating malignant cells in the pleural fluid or pleural tissue biopsies. The effusion seen in cases where the malignancy does not directly affect the pleura is called a premalignant effusion[19].
The most common mechanism of pleural effusion in patients with malignant disease is lymphatic obstruction[4,19,20]. The most common cause of malignant effusion in women is breast and ovary cancer metastasis while lung cancer and malignant mesothelioma affect both sexes equally[21]. Bayrak et al.[22] have found lung cancer to take first place among causes of malignant pleural effusion, followed by breast cancer, mesothelioma and lymphoma. Although primary pleural malignancies are seen less commonly, the incidence of malignant mesothelioma is increased in areas with asbestos exposure[23]. Arbak et al.[24] found primary lung carcinomas to take first place among malignancyassociated pleural effusion causes followed by tumors metastasizing to the pleura. Metastatic carcinomas took first place among the causes of malignant pleural effusion in our study and lung, breast and ovary tumors were the most common. The frequency of mesotheliomas, taking second place, was noteworthy. This may be due to the fact that our hospital serves the Elazığ province and surrounding areas that have a large number of persons exposed to asbestos. Özkara et al.[23] have found mesothelioma to take first place as the cause of malignant effusion in their study, followed by lung cancers.
It is not possible to find a primary cancer focus in 4.7% of patients with a malignant effusion[4]. We found a tumor with unknown primary in 4 of the 18 cases diagnosed with a metastatic carcinoma and did not have a biopsy. The rate of malignant pleural effusion can reach 40-87% in different series on cytopathologic investigation. It is easy to diagnose adenocarcinoma with pleural cytology while diagnosing squamous cell carcinoma, Hodgkin’s lymphoma and sarcoma is quite difficult[5]. In our study, 24 of the 31 cases receiving a diagnosis of malignant on cytology were diagnosed as metastatic carcinoma and 7 of these were diagnosed as lung adenocarcinoma with 2 having and 5 not having a biopsy. One case was diagnosed as pleural liposarcoma.
The sensitivity of pleural tissue biopsy in the diagnosis of malignant pleurisy is lower than that of cytopathologic evaluation. Very few cases negative on cytology can be diagnosed by biopsy[5]. The diagnosis was benign in 246 (82.6%) of 298 pleural fluid cases in our study.
In conclusion, cytopathologic investigation for pleural fluid is fast, rapid, noninvasive and is very important regarding treatment and prognosis as it constitutes the primary diagnostic step. Although the etiology of pleural effusions vary, the most common causes of malignant pleural effusion in our country are metastatic carcinomas and especially lung, breast and ovary tumors. Malignant mesotheliomas take second place.
1) Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr: Pleural
effusions: The diagnostic separation of transudates and exsudates.
Ann Intern Med 1972, 77: 507-513 [ Özet ]
2) Loddenkemper R, Antony VB: Introduction. Eur Respir Mon
2002, 22: C
3) Light RW: Diagnostic approach in a patient with pleural effusion.
Eur Respir Mon 2002, 22: 131-145
4) Marel M: Epidemiology of pleural effusions. Eur Respir Mon
2002, 22: 146-156
5) Light RW: Pleural diseases. 4th ed. Philadelphia, Lippincott
Williams and Wilkins, 2001, 120-123
6) Polatlı M, Aysan T, Erdinç M, Günel Ö: Plevra sıvı sitolojisi ve
plevra biyopsisinin tanı değeri. Tuberk Toraks 1997, 45: 12-15
7) Christopher DJ, Peter JV, Cherian AM: Blind pleural biopsy
using a Tru-cut needle in moderate to large pleural effusion-an
experience. Singapore Med J 1998, 39: 196-199 [ Özet ]
8) Uzunlar AK, Büyükbayram H, Kırbaş G, Yaldız M, Yılmaz F,
Arslan A: Plevral sıvı sitolojisi ve biyopsisinin tanı değeri (Bir
Retrospektif Çalışma). Solunum Hastalık 2000, 11: 169-173
9) Prakash UB, Reiman HM: Comparison of needle biopsy with
cytologic analysis for the evaluation of pleural effusion: analysis
of 414 cases. Mayo Clin Proc 1985, 60: 158-64 [ Özet ]
10) Ardıç S, Artvinli M, Şahin AA, Özdemir N: Plevral effüzyonların
tanısında tanı yöntemlerinin başarısı. Solunum 1987, 12: 594-604
11) Özesmi M, Tuncer M: Plörezide klinik yaklaşım. Solunum 1983,
8: 207-214
12) Hackbarth JS, Murata K, Reilly WM, Algeciras-Schimnich
A: Performance of CEA and CA19-9 in identifying pleural
effusions caused by specific malignancies. Clin Biochem 2010, 43:
1051-1055 [ Özet ]
13) Tufan M, Polatlı M, Bayındır Ü: Plevra sıvısı ve serumda
bilirubin konsantrasyonları ve albumin gradienti. Solunum 1991,
16: 510-515
14) Adams VI, Unni KK, Muhm RJ, Jett JR, Ilstrup DM, Bernatz PE:
Diffuse malignant mesotelioma of pleura. Diagnosis and survival
in 92 cases. Cancer 1986, 58: 1540-1551 [ Özet ]
15) Gönlügür TE, Gönlügür U: 454 Plevral efüzyonun retrospektif
analizi. İnönü Üniv Tıp Fak Derg 2007, 14: 21-25
16) Storey DD, Dines DE, Coles DT: Pleural effusion: a diagnostic
dilemma. JAMA 1976, 236: 2183-2186 [ Özet ]
17) Hirsch A, Ruffie P, Nebut M, Bignon J, Chrétien J: Pleural
effusion: Laboratory test in 300 cases. Thorax 1979, 34: 106-112 [ Özet ]
18) Porcel JM, Aleman C, Bielsa S, Sarrapio J, Fernandez de Sevilla
T, Esquerda A: A decision tree for differentiating tuberculous
from malignant pleural effusions. Respir Med 2008, 102:
1159-1164 [ Özet ]
19) Sahn SA: Pleural diseases related to metastatic malignancies. Eur
Respir J 1997, 10: 1907-1913 [ Özet ]
20) Sahn SA: Malignant pleural effusions. Eur Respir Mon 2002, 22:
177-188
21) Slipicevic A, Frode G, Askildt IC, Holth A, Hellesylt E, Florenes
VA, Davidson B: Diagnostic and prognostic role of insulin
growth factor pathway members insulin-like growth factor-II and
insulin-like growth factor binding protein-3 in serous effusions.
Hum Pathol 2009, 40: 527-537 [ Özet ]
22) Bayrak MG, Erkan L, Uzun O, Fındık S, Atıcı AG, Özkaya Ş:
Plevral efüzyonlu 153 hastanın değerlendirilmesi. Solunum
Hastalık 2006, 17: 66-67